We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go: 16 investment: Withheld
Qure are an affordable and convenient on-demand healthcare service providing a doctor to users doors within 2 hours, 24/7. The hassle-free healthcare connects individuals with highly-experienced medical practitioners in the local area. 
days to go: Expired investment: £720,000
Riders can enjoy indoor cycling within a boutique fitness studio. In the past 6 years, Boom Cycle have opened five sites are now seeking funds to expand their portfolio. To date, Boom Cycle has acquired over £4.1m from private investors and in 2017 spent £2.1m on developing two flagship studios. The company has experienced attendance growth of 47% YoY, as well as a 77% increase in revenue YoY.
days to go: Expired investment: £805,260
paus is an on-demand streaming service. It offers specialist, hand-picked independent films to today's streamers who wish to avail a niche streaming service in 2020. The company aims to propel curated independent cinema into the $161 billion global streaming market by replacing conventional subscription and ad-based models with a peer-to-peer digital tipping model. paus is working with globally recognised film institutions to procure curated content. Over 1,900 people have signed up for early access to its iOS app. The company is currently rolling out a beta iOS version in the UK and US. It will use the investment to move into streaming theatre and web-series on its portal.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £352,724
PathCloud aims to assemble the global clinical diagnostics resources and data and make them safely available and helpful. The company has created and tested one of the first scalable clinical diagnostics management platforms. It currently has 20,000 clinicians partner networks and 92 registered clinicians. Additionally, it has a network across 48 counties, has over 100 providers, over 3500 diagnostics tests registered and over 10,000 patients by partner telemedicine networks. These funds will be used to gain a significant portion of diagnostics supplier agreements towards the scaling objective, increase efforts towards the international markets and NHS and pursue telemedicine networks.
days to go: Expired investment: £81,720
Next-generation wellbeing analytics for individuals and organisations – boosts happiness and productivity
days to go: Expired investment: £768,597
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £522,689
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph